Flagship explainer
What drives Sarepta Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$713M | FY2025 |
| |
| Income before tax | −$702M | FY2025 |
|
| Operating income | −$700M | FY2025 |
|
| $1.9B | FY2025 |
| |
| Ending assets | $3.3B | FY2025 |
|
| Beginning assets | $4.0B | FY2024 |
|
| $1.1B | FY2025 |
| |
| $1.5B | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-084144